Will newly-joined domestic pharmaceutical companies be successful in DPP-4 diabetic treatment market?

The DPP-4 inhibitor diabetes treatment market, which has been occupied by Januvia and Trajenta, has recently been invaded by domestic pharmaceutical companies.

Handok has made progress in commercializing ambitiously prepared ‘Tenelia,’ a single drug, after the end of the Galvus’s sales license, and at the same time, has aggressively aimed for the market by launching ‘Tenelia M,’ a complex drug...